Moneycontrol
Get App
Last Updated : Jan 12, 2013 04:04 PM IST | Source: Moneycontrol.com

See pharma sector's Q3 topline to grow 22%: Motilal Oswal

Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.

Motilal Oswal's report on Q3FY13 earnings estimates of pharma sector:

For 3QFY13, we expect topline growth of 22 percent YoY and EBITDA growth of 21 percent YoY for our Pharma Universe (excluding one-offs). Adjusted PAT is likely to grow 33.5 percent YoY.

EBITDA growth would be mainly led by strong performance by Ranbaxy, Glenmark, Strides and Torrent, which would witness high growth over a low base in 3QFY12. EBITDA growth would be higher than sales growth for Cipla and Divi's, aided by increased capacity utilization. Dr. Reddy's and Cadila too will report healthy operating performance driven by new product launches. Operating performance would also be partially driven by favorable currency.

Adjusted PAT growth at 33.5 percent would be higher than EBITDA growth, mainly because of high forex losses in 3QFY12 on account of appreciation of the INR v/s the USD.

Expected quarterly performance summary (INR million)

Company

Sales

Net Profit

Dec.12

Var.

Var.

Dec.12

Var.

Var.

 

% YoY

% QoQ

 

% YoY

% QoQ

Biocon6,15218.93.8821-3.2-8.4
Cadila Health16,743218.31,84223.493.6
Cipla20,17114.72.63,25420.5-18.4
Dishman Pharma3,21521.111.118711.7-29.7
Divis Labs5,41030.514.51,47520.325
Dr Reddy's26,82323.11.33,41742.11.9
Glenmark Pharma12,29625.70.81,4761842.23.6
GSK Pharma6,2189.8-71,463-0.7-10.6
IPCA Labs7,29218.6-5.588738.7-29.1
Jubilant Life12,99819.66.6574LP-48.5
Lupin22,56627.41.92,849142.5
Opto Circuits7,29719.420.21,3749.718.2
Ranbaxy28,61634.716.72,23643.7-17.6
Sanofi India3,93216.4-0.93774.5-26.6
Strides Arcolab6,697-2.4161,02349.695
Sun Pharma24,75721.50.77,01214.8-15.7
Torrent Pharma8,35019.97.41,14938.17.1
Sector Aggregate219,53321.85.231,41533.5-5.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Note: Historic numbers exclude upside from one-off opportunities

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.



Exclusive offer: Use code "BUDGET2020" and get Moneycontrol Pro's Subscription for as little as Rs 333/- for the first year.
First Published on Jan 12, 2013 11:54 am
Sections
Follow us on